Table 3.
Univariate and multivariate logistic regression analysis for risk factors for IMDC recurrence
| Variable | Univariate analysis | Multivariate analysis | ||||
| OR | 95% CI | P value | OR | 95% CI | P value | |
| Charlson Comorbidity Index | 1.03 | 0.87 to 1.21 | 0.775 | |||
| Duration of ICI treatment | 1.01 | 1.00 to 1.05 | 0.004 | |||
| ICI type | ||||||
| Anti-CTLA-4 | Reference | |||||
| Anti-PD-(L)−1 | 1.6 | 0.43 to 3.09 | 0.771 | |||
| Combination | 0.49 | 0.16 to 1.49 | 0.210 | |||
| Duration from ICI to IMDC onset | 1.09 | 1.03 to 1.15 | 0.002 | 1.09 | 1.03 to 1.15 | 0.002 |
| Duration of colitis symptoms | 1.01 | 0.99 to 1.02 | 0.487 | |||
| Diarrhea grade 3–4 vs 1–2 | 1.06 | 0.51 to 2.21 | 0.879 | |||
| Colitis grade 3–4 vs 1–2 | 0.98 | 0.48 to 1.94 | 0.911 | |||
| Overall duration of steroids | 1.44 | 1.01 to 2.06 | 0.043 | 1.48 | 1.03 to 2.12 | 0.033 |
| IV steroids | 1.59 | 0.76 to 3.33 | 0.223 | |||
| Type of SIT | ||||||
| Vedolizumab | Reference | |||||
| Infliximab | 2.51 | 1.05 to 5.99 | 0.039 | |||
| Both sequentially | 2.86 | 0.89 to 9.19 | 0.078 | |||
| Dose of SIT | 1.04 | 0.91 to 1.18 | 0.613 | |||
| Time from IMDC to first dose of SIT | 1.00 | 0.98 to 1.01 | 0.064 | |||
CTLA-4, cytotoxic T-lymphocyte-associated protein 4; ICI, immune checkpoint inhibitor; IMDC, immune-mediated diarrhea and colitis; IV, intravenous; PD-(L)−1, programmed cell death 1 protein/ligand; SIT, selective immunosuppressive therapy.